aveni-ai/aveni-bench-tat-qa huggingface dataset:
Cash Flow Hedges For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain or loss on the derivative is reported as a component of AOCI and reclassified into earnings in the same period or periods during which the hedged transactions affect earnings or it becomes probable the forecasted transactions will not occur. The following is a summary of the gains (losses) related to cash flow hedges recognized during the years ended June 30, 2019, 2018 and 2017:

Amount of Gain (Loss) Recognized in AOCI on Derivatives

Years Ended June 30,

($ in millions)	2019	2018	2017

Derivatives in Cash Flow Hedging Relationship:

Commodity contracts	$45.4	$41.4	$9.4

Foreign exchange contracts	(0.9)	(0.4)	(0.1)

Total	$44.5	$41.0	$9.3

Question: In which years were cash flow hedges calculated?
Answer: 2019; 2018; 2017
Cash Flow Hedges For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain or loss on the derivative is reported as a component of AOCI and reclassified into earnings in the same period or periods during which the hedged transactions affect earnings or it becomes probable the forecasted transactions will not occur. The following is a summary of the gains (losses) related to cash flow hedges recognized during the years ended June 30, 2019, 2018 and 2017:

Amount of Gain (Loss) Recognized in AOCI on Derivatives

Years Ended June 30,

($ in millions)	2019	2018	2017

Derivatives in Cash Flow Hedging Relationship:

Commodity contracts	$45.4	$41.4	$9.4

Foreign exchange contracts	(0.9)	(0.4)	(0.1)

Total	$44.5	$41.0	$9.3

Question: In which year was the amount of commodity contracts the largest?
Answer: 2019
Cash Flow Hedges For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain or loss on the derivative is reported as a component of AOCI and reclassified into earnings in the same period or periods during which the hedged transactions affect earnings or it becomes probable the forecasted transactions will not occur. The following is a summary of the gains (losses) related to cash flow hedges recognized during the years ended June 30, 2019, 2018 and 2017:

Amount of Gain (Loss) Recognized in AOCI on Derivatives

Years Ended June 30,

($ in millions)	2019	2018	2017

Derivatives in Cash Flow Hedging Relationship:

Commodity contracts	$45.4	$41.4	$9.4

Foreign exchange contracts	(0.9)	(0.4)	(0.1)

Total	$44.5	$41.0	$9.3

Question: What was the change in the Total amount in 2019 from 2018?
Answer: 3.5
Cash Flow Hedges For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain or loss on the derivative is reported as a component of AOCI and reclassified into earnings in the same period or periods during which the hedged transactions affect earnings or it becomes probable the forecasted transactions will not occur. The following is a summary of the gains (losses) related to cash flow hedges recognized during the years ended June 30, 2019, 2018 and 2017:

Amount of Gain (Loss) Recognized in AOCI on Derivatives

Years Ended June 30,

($ in millions)	2019	2018	2017

Derivatives in Cash Flow Hedging Relationship:

Commodity contracts	$45.4	$41.4	$9.4

Foreign exchange contracts	(0.9)	(0.4)	(0.1)

Total	$44.5	$41.0	$9.3

Question: What was the percentage change in the Total amount in 2019 from 2018?
Answer: 8.54
The weighted-average grant date fair value of VMware stock options can fluctuate from period to period primarily due to higher valued options assumed through business combinations with exercise prices lower than the fair market value of VMware’s stock on the date of grant. For equity awards granted under the VMware equity plan, volatility was based on an analysis of historical stock prices and implied volatilities of VMware’s Class A common stock. The expected term was based on historical exercise patterns and post-vesting termination behavior, the term of the option period for grants made under the ESPP, or the weighted-average remaining term for options assumed in acquisitions. VMware’s expected dividend yield input was zero as the Company has not historically paid, nor expects in the future to pay, regular dividends on its common stock. The risk-free interest rate was based on a U.S. Treasury instrument whose term is consistent with the expected term of the stock options. For equity awards granted under the Pivotal equity plan, volatility was based on the volatility of a group of comparable public companies based on size, stage of life cycle, profitability, growth and other factors. The expected term was estimated using the simplified method and was determined based on the vesting terms, exercise terms and contractual lives of the options. Pivotal’s expected dividend yield input was zero as the Company has not historically paid regular dividends on its common stock. The risk-free interest rate was based on a U.S. Treasury instrument whose term was consistent with the expected term of the stock options.

For the Year Ended

VMware Employee Stock Purchase Plan	January 31, 2020	February 1, 2019	February 2, 2018

Dividend yield	None	None	None

Expected volatility	27.4%	33.5%	22.6%

Risk-free interest rate	1.7%	2.0%	1.2%

Expected term (in years)	0.6	0.8	0.9

Weighted-average fair value at grant date	$35.66	$34.72	$21.93

Question: What was the Weighted-average fair value at grant date in 2020?
Answer: $35.66
The weighted-average grant date fair value of VMware stock options can fluctuate from period to period primarily due to higher valued options assumed through business combinations with exercise prices lower than the fair market value of VMware’s stock on the date of grant. For equity awards granted under the VMware equity plan, volatility was based on an analysis of historical stock prices and implied volatilities of VMware’s Class A common stock. The expected term was based on historical exercise patterns and post-vesting termination behavior, the term of the option period for grants made under the ESPP, or the weighted-average remaining term for options assumed in acquisitions. VMware’s expected dividend yield input was zero as the Company has not historically paid, nor expects in the future to pay, regular dividends on its common stock. The risk-free interest rate was based on a U.S. Treasury instrument whose term is consistent with the expected term of the stock options. For equity awards granted under the Pivotal equity plan, volatility was based on the volatility of a group of comparable public companies based on size, stage of life cycle, profitability, growth and other factors. The expected term was estimated using the simplified method and was determined based on the vesting terms, exercise terms and contractual lives of the options. Pivotal’s expected dividend yield input was zero as the Company has not historically paid regular dividends on its common stock. The risk-free interest rate was based on a U.S. Treasury instrument whose term was consistent with the expected term of the stock options.

For the Year Ended

VMware Employee Stock Purchase Plan	January 31, 2020	February 1, 2019	February 2, 2018

Dividend yield	None	None	None

Expected volatility	27.4%	33.5%	22.6%

Risk-free interest rate	1.7%	2.0%	1.2%

Expected term (in years)	0.6	0.8	0.9

Weighted-average fair value at grant date	$35.66	$34.72	$21.93

Question: Why would the weighted-average grant date fair value of VMware stock options fluctuate?
Answer: due to higher valued options assumed through business combinations with exercise prices lower than the fair market value of VMware’s stock on the date of grant.
The weighted-average grant date fair value of VMware stock options can fluctuate from period to period primarily due to higher valued options assumed through business combinations with exercise prices lower than the fair market value of VMware’s stock on the date of grant. For equity awards granted under the VMware equity plan, volatility was based on an analysis of historical stock prices and implied volatilities of VMware’s Class A common stock. The expected term was based on historical exercise patterns and post-vesting termination behavior, the term of the option period for grants made under the ESPP, or the weighted-average remaining term for options assumed in acquisitions. VMware’s expected dividend yield input was zero as the Company has not historically paid, nor expects in the future to pay, regular dividends on its common stock. The risk-free interest rate was based on a U.S. Treasury instrument whose term is consistent with the expected term of the stock options. For equity awards granted under the Pivotal equity plan, volatility was based on the volatility of a group of comparable public companies based on size, stage of life cycle, profitability, growth and other factors. The expected term was estimated using the simplified method and was determined based on the vesting terms, exercise terms and contractual lives of the options. Pivotal’s expected dividend yield input was zero as the Company has not historically paid regular dividends on its common stock. The risk-free interest rate was based on a U.S. Treasury instrument whose term was consistent with the expected term of the stock options.

For the Year Ended

VMware Employee Stock Purchase Plan	January 31, 2020	February 1, 2019	February 2, 2018

Dividend yield	None	None	None

Expected volatility	27.4%	33.5%	22.6%

Risk-free interest rate	1.7%	2.0%	1.2%

Expected term (in years)	0.6	0.8	0.9

Weighted-average fair value at grant date	$35.66	$34.72	$21.93

Question: What was the expected term in 2019 in years?
Answer: 0.6
The weighted-average grant date fair value of VMware stock options can fluctuate from period to period primarily due to higher valued options assumed through business combinations with exercise prices lower than the fair market value of VMware’s stock on the date of grant. For equity awards granted under the VMware equity plan, volatility was based on an analysis of historical stock prices and implied volatilities of VMware’s Class A common stock. The expected term was based on historical exercise patterns and post-vesting termination behavior, the term of the option period for grants made under the ESPP, or the weighted-average remaining term for options assumed in acquisitions. VMware’s expected dividend yield input was zero as the Company has not historically paid, nor expects in the future to pay, regular dividends on its common stock. The risk-free interest rate was based on a U.S. Treasury instrument whose term is consistent with the expected term of the stock options. For equity awards granted under the Pivotal equity plan, volatility was based on the volatility of a group of comparable public companies based on size, stage of life cycle, profitability, growth and other factors. The expected term was estimated using the simplified method and was determined based on the vesting terms, exercise terms and contractual lives of the options. Pivotal’s expected dividend yield input was zero as the Company has not historically paid regular dividends on its common stock. The risk-free interest rate was based on a U.S. Treasury instrument whose term was consistent with the expected term of the stock options.

For the Year Ended

VMware Employee Stock Purchase Plan	January 31, 2020	February 1, 2019	February 2, 2018

Dividend yield	None	None	None

Expected volatility	27.4%	33.5%	22.6%

Risk-free interest rate	1.7%	2.0%	1.2%

Expected term (in years)	0.6	0.8	0.9

Weighted-average fair value at grant date	$35.66	$34.72	$21.93

Question: Which years did expected term exceed 0.5 years?
Answer: 2020; 2019; 2018
The weighted-average grant date fair value of VMware stock options can fluctuate from period to period primarily due to higher valued options assumed through business combinations with exercise prices lower than the fair market value of VMware’s stock on the date of grant. For equity awards granted under the VMware equity plan, volatility was based on an analysis of historical stock prices and implied volatilities of VMware’s Class A common stock. The expected term was based on historical exercise patterns and post-vesting termination behavior, the term of the option period for grants made under the ESPP, or the weighted-average remaining term for options assumed in acquisitions. VMware’s expected dividend yield input was zero as the Company has not historically paid, nor expects in the future to pay, regular dividends on its common stock. The risk-free interest rate was based on a U.S. Treasury instrument whose term is consistent with the expected term of the stock options. For equity awards granted under the Pivotal equity plan, volatility was based on the volatility of a group of comparable public companies based on size, stage of life cycle, profitability, growth and other factors. The expected term was estimated using the simplified method and was determined based on the vesting terms, exercise terms and contractual lives of the options. Pivotal’s expected dividend yield input was zero as the Company has not historically paid regular dividends on its common stock. The risk-free interest rate was based on a U.S. Treasury instrument whose term was consistent with the expected term of the stock options.

For the Year Ended

VMware Employee Stock Purchase Plan	January 31, 2020	February 1, 2019	February 2, 2018

Dividend yield	None	None	None

Expected volatility	27.4%	33.5%	22.6%

Risk-free interest rate	1.7%	2.0%	1.2%

Expected term (in years)	0.6	0.8	0.9

Weighted-average fair value at grant date	$35.66	$34.72	$21.93

Question: What was the absolute percentage change in risk-free interest rate between 2018 and 2019?
Answer: 0.8
The weighted-average grant date fair value of VMware stock options can fluctuate from period to period primarily due to higher valued options assumed through business combinations with exercise prices lower than the fair market value of VMware’s stock on the date of grant. For equity awards granted under the VMware equity plan, volatility was based on an analysis of historical stock prices and implied volatilities of VMware’s Class A common stock. The expected term was based on historical exercise patterns and post-vesting termination behavior, the term of the option period for grants made under the ESPP, or the weighted-average remaining term for options assumed in acquisitions. VMware’s expected dividend yield input was zero as the Company has not historically paid, nor expects in the future to pay, regular dividends on its common stock. The risk-free interest rate was based on a U.S. Treasury instrument whose term is consistent with the expected term of the stock options. For equity awards granted under the Pivotal equity plan, volatility was based on the volatility of a group of comparable public companies based on size, stage of life cycle, profitability, growth and other factors. The expected term was estimated using the simplified method and was determined based on the vesting terms, exercise terms and contractual lives of the options. Pivotal’s expected dividend yield input was zero as the Company has not historically paid regular dividends on its common stock. The risk-free interest rate was based on a U.S. Treasury instrument whose term was consistent with the expected term of the stock options.

For the Year Ended

VMware Employee Stock Purchase Plan	January 31, 2020	February 1, 2019	February 2, 2018

Dividend yield	None	None	None

Expected volatility	27.4%	33.5%	22.6%

Risk-free interest rate	1.7%	2.0%	1.2%

Expected term (in years)	0.6	0.8	0.9

Weighted-average fair value at grant date	$35.66	$34.72	$21.93

Question: What was the absolute percentage change in Expected volatility between 2019 and 2020?
Answer: -6.1
Horizon Clinicals and Series2000 Revenue Cycle Discontinued Operation Two of the product offerings acquired with the EIS Business in 2017, Horizon Clinicals and Series2000 Revenue Cycle, were sunset after March 31, 2018. The decision to discontinue maintaining and supporting these solutions was made prior to our acquisition of the EIS Business and, therefore, they are presented below as discontinued operations. Until the end of the first quarter of 2018, we were involved in ongoing maintenance and support for these solutions until customers transitioned to other platforms. No disposal gains or losses were recognized during the year ended December 31, 2018 related to these discontinued solutions. We had $0.9 million of accrued expenses associated with the Horizon Clinicals and Series2000 Revenue Cycle businesses on the consolidated balance sheets as of December 31, 2018 The following table summarizes the major income and expense line items of these discontinued solutions, as reported in the consolidated statements of operations for the years ended December 31, 2018 and 2017:

(In thousands)	2018	2017

Major classes of line items constituting pretax profit (loss) of discontinued operations for Horizon Clinicals and Series2000 Revenue Cycle:

Revenue:

Software delivery, support and maintenance	$9,441	$10,949

Client services	404	1,044

Total revenue	9,845	11,993

Cost of revenue:

Software delivery, support and maintenance	2,322	2,918

Client services	830	261

Total cost of revenue	3,152	3,179

Gross profit	6,693	8,814

Research and development	1,651	1,148

Income from discontinued operations for Horizon Clinicals and Series2000 Revenue Cycle before income taxes	5,042	7,666

Income tax provision	(1,311)	(2,990)

Income from discontinued operations, net of tax for Horizon Clinicals and Series2000 Revenue Cycle	$3,731	$4,676

Question: Which product offerings were acquired with the EIS Business in 2017?
Answer: Horizon Clinicals and Series2000 Revenue Cycle
Horizon Clinicals and Series2000 Revenue Cycle Discontinued Operation Two of the product offerings acquired with the EIS Business in 2017, Horizon Clinicals and Series2000 Revenue Cycle, were sunset after March 31, 2018. The decision to discontinue maintaining and supporting these solutions was made prior to our acquisition of the EIS Business and, therefore, they are presented below as discontinued operations. Until the end of the first quarter of 2018, we were involved in ongoing maintenance and support for these solutions until customers transitioned to other platforms. No disposal gains or losses were recognized during the year ended December 31, 2018 related to these discontinued solutions. We had $0.9 million of accrued expenses associated with the Horizon Clinicals and Series2000 Revenue Cycle businesses on the consolidated balance sheets as of December 31, 2018 The following table summarizes the major income and expense line items of these discontinued solutions, as reported in the consolidated statements of operations for the years ended December 31, 2018 and 2017:

(In thousands)	2018	2017

Major classes of line items constituting pretax profit (loss) of discontinued operations for Horizon Clinicals and Series2000 Revenue Cycle:

Revenue:

Software delivery, support and maintenance	$9,441	$10,949

Client services	404	1,044

Total revenue	9,845	11,993

Cost of revenue:

Software delivery, support and maintenance	2,322	2,918

Client services	830	261

Total cost of revenue	3,152	3,179

Gross profit	6,693	8,814

Research and development	1,651	1,148

Income from discontinued operations for Horizon Clinicals and Series2000 Revenue Cycle before income taxes	5,042	7,666

Income tax provision	(1,311)	(2,990)

Income from discontinued operations, net of tax for Horizon Clinicals and Series2000 Revenue Cycle	$3,731	$4,676

Question: What was the Software delivery, support and maintenance revenue in 2018?
Answer: $9,441
Horizon Clinicals and Series2000 Revenue Cycle Discontinued Operation Two of the product offerings acquired with the EIS Business in 2017, Horizon Clinicals and Series2000 Revenue Cycle, were sunset after March 31, 2018. The decision to discontinue maintaining and supporting these solutions was made prior to our acquisition of the EIS Business and, therefore, they are presented below as discontinued operations. Until the end of the first quarter of 2018, we were involved in ongoing maintenance and support for these solutions until customers transitioned to other platforms. No disposal gains or losses were recognized during the year ended December 31, 2018 related to these discontinued solutions. We had $0.9 million of accrued expenses associated with the Horizon Clinicals and Series2000 Revenue Cycle businesses on the consolidated balance sheets as of December 31, 2018 The following table summarizes the major income and expense line items of these discontinued solutions, as reported in the consolidated statements of operations for the years ended December 31, 2018 and 2017:

(In thousands)	2018	2017

Major classes of line items constituting pretax profit (loss) of discontinued operations for Horizon Clinicals and Series2000 Revenue Cycle:

Revenue:

Software delivery, support and maintenance	$9,441	$10,949

Client services	404	1,044

Total revenue	9,845	11,993

Cost of revenue:

Software delivery, support and maintenance	2,322	2,918

Client services	830	261

Total cost of revenue	3,152	3,179

Gross profit	6,693	8,814

Research and development	1,651	1,148

Income from discontinued operations for Horizon Clinicals and Series2000 Revenue Cycle before income taxes	5,042	7,666

Income tax provision	(1,311)	(2,990)

Income from discontinued operations, net of tax for Horizon Clinicals and Series2000 Revenue Cycle	$3,731	$4,676

Question: How much was the accrued expenses associated with the Horizon Clinicals and Series2000 Revenue Cycle businesses on the consolidated balance sheets as of December 31, 2018?
Answer: $0.9 million
Horizon Clinicals and Series2000 Revenue Cycle Discontinued Operation Two of the product offerings acquired with the EIS Business in 2017, Horizon Clinicals and Series2000 Revenue Cycle, were sunset after March 31, 2018. The decision to discontinue maintaining and supporting these solutions was made prior to our acquisition of the EIS Business and, therefore, they are presented below as discontinued operations. Until the end of the first quarter of 2018, we were involved in ongoing maintenance and support for these solutions until customers transitioned to other platforms. No disposal gains or losses were recognized during the year ended December 31, 2018 related to these discontinued solutions. We had $0.9 million of accrued expenses associated with the Horizon Clinicals and Series2000 Revenue Cycle businesses on the consolidated balance sheets as of December 31, 2018 The following table summarizes the major income and expense line items of these discontinued solutions, as reported in the consolidated statements of operations for the years ended December 31, 2018 and 2017:

(In thousands)	2018	2017

Major classes of line items constituting pretax profit (loss) of discontinued operations for Horizon Clinicals and Series2000 Revenue Cycle:

Revenue:

Software delivery, support and maintenance	$9,441	$10,949

Client services	404	1,044

Total revenue	9,845	11,993

Cost of revenue:

Software delivery, support and maintenance	2,322	2,918

Client services	830	261

Total cost of revenue	3,152	3,179

Gross profit	6,693	8,814

Research and development	1,651	1,148

Income from discontinued operations for Horizon Clinicals and Series2000 Revenue Cycle before income taxes	5,042	7,666

Income tax provision	(1,311)	(2,990)

Income from discontinued operations, net of tax for Horizon Clinicals and Series2000 Revenue Cycle	$3,731	$4,676

Question: What is the change in Revenue of Software delivery, support and maintenance between 2017 and 2018?
Answer: -1508